



MEN

FIRST CANCER SITE  
COLONCOLON  
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

COLON  
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
<b>SECOND CANCER SITE</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>EAR</b>	<b>EAR</b>
ALL SITES, BUT SKIN AND COLON	5145	<b>0.93</b>	6014	<b>1.04</b>	869	<b>3.67</b>	819	<b>0.86</b>	2342	<b>0.89</b>	1347	0.98	637	1.04	<b>-1.58</b>	<b>0.81</b>
HEAD AND NECK	194	<b>0.86</b>	205	<b>0.86</b>	11	1.06	26	<b>0.62</b>	101	0.92	47	0.89	20	0.92	-0.13	-0.12
ORAL CAVITY	47	0.88	50	0.90	3	1.25	10	1.03	21	0.82	12	0.96	4	0.76	-0.02	-0.02
PHARYNX	30	<b>0.65</b>	34	<b>0.70</b>	4	1.88	2	<b>0.23</b>	19	0.84	7	0.66	2	0.46	-0.06	-0.05
LARYNX	117	0.92	121	0.91	4	0.68	14	<b>0.59</b>	61	0.98	28	0.94	14	1.15	-0.04	-0.05
OESOPHAGUS	54	0.87	65	1.01	11	<b>4.00</b>	10	0.91	25	0.84	14	0.95	5	0.78	-0.03	0.00
STOMACH	337	<b>0.88</b>	368	0.92	31	<b>1.84</b>	35	<b>0.53</b>	152	<b>0.84</b>	103	1.10	47	1.14	-0.17	-0.11
COLON RECTUM	228	<b>0.27</b>	304	<b>0.34</b>	76	<b>2.13</b>	54	<b>0.38</b>	133	<b>0.33</b>	26	<b>0.12</b>	15	<b>0.15</b>	<b>-2.40</b>	<b>-2.15</b>
COLON	7	<b>0.01</b>	22	<b>0.04</b>	15	0.61	3	<b>0.03</b>	3	<b>0.01</b>	1	<b>0.01</b>	0	<b>0.00</b>	<b>-2.24</b>	<b>-2.18</b>
RECTUM	221	<b>0.84</b>	282	1.03	61	<b>5.42</b>	51	1.13	130	1.05	25	<b>0.39</b>	15	<b>0.52</b>	-0.16	0.03
LIVER	189	<b>0.79</b>	251	1.00	62	<b>5.98</b>	32	0.77	74	<b>0.65</b>	55	0.94	28	1.08	<b>-0.20</b>	0.00
GALLBLADDER	57	0.84	61	0.86	4	1.39	4	<b>0.35</b>	25	0.78	20	1.17	8	1.02	-0.04	-0.04
PANCREAS	144	0.86	152	0.87	8	1.14	26	0.92	56	<b>0.71</b>	40	0.96	22	1.15	-0.09	-0.08
LUNG	882	<b>0.83</b>	1012	<b>0.92</b>	130	<b>2.82</b>	148	<b>0.80</b>	379	<b>0.75</b>	251	0.98	104	0.92	<b>-0.67</b>	<b>-0.34</b>
SKIN MELANOMA	103	<b>1.27</b>	114	<b>1.35</b>	11	<b>3.34</b>	15	1.11	46	1.22	29	1.43	13	1.38	0.08	<b>0.11</b>
MESOTHELIOMA	23	0.73	26	0.79	3	2.32	1	0.19	16	1.08	5	0.64	1	0.28	-0.03	-0.02
KAPOSI SARCOMA	18	1.42	19	1.43	1	1.80	2	0.91	9	1.50	5	1.62	2	1.40	0.02	0.02
SOFT TISSUE	15	0.73	21	0.98	6	<b>6.92</b>	3	0.86	7	0.73	4	0.79	1	0.43	-0.02	0.00
BONE	4	0.78	4	0.75	0	0.00	0	0.00	1	0.41	2	1.66	1	1.95	0.00	0.00
BREAST	14	1.08	17	1.26	3	<b>5.47</b>	1	0.45	6	0.99	5	1.56	2	1.38	0.00	0.01
PROSTATE	1271	1.03	1416	<b>1.10</b>	145	<b>2.89</b>	184	0.90	549	0.95	370	<b>1.19</b>	168	<b>1.19</b>	0.14	<b>0.48</b>
TESTIS	10	1.89	11	1.98	1	4.03	0	0.00	6	2.32	3	2.47	1	2.02	0.02	0.02
KIDNEY AND RENAL PELVIS	250	<b>1.36</b>	406	<b>2.12</b>	156	<b>20.20</b>	72	<b>2.30</b>	112	<b>1.29</b>	44	0.97	22	1.09	<b>0.26</b>	<b>0.79</b>
BLADDER AND URINARY TRACT	670	0.98	793	<b>1.11</b>	123	<b>4.20</b>	97	0.83	341	1.05	149	0.88	83	1.09	-0.06	<b>0.29</b>
URINARY BLADDER	639	0.97	757	<b>1.11</b>	118	<b>4.21</b>	96	0.85	326	1.05	142	0.88	75	1.03	-0.06	0.27
URINARY TRACT	31	1.01	36	1.13	5	<b>3.92</b>	1	0.20	15	1.05	7	0.92	8	2.25	0.00	0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	50	0.77	51	<b>0.75</b>	1	0.35	10	0.87	15	<b>0.48</b>	15	0.96	10	1.49	-0.06	-0.06
THYROID	45	<b>1.89</b>	49	<b>1.97</b>	4	<b>3.91</b>	9	2.14	22	<b>1.93</b>	10	1.75	4	1.63	<b>0.08</b>	<b>0.09</b>
HODGKIN LYMPHOMA	11	1.05	15	1.37	4	<b>8.30</b>	4	2.06	3	0.59	4	1.63	0	0.00	0.00	0.01
NON-HODGKIN LYMPHOMA	150	0.89	187	1.07	37	<b>5.20</b>	27	0.94	66	0.83	33	0.80	24	1.29	-0.07	0.04
MYELOMA	76	0.93	77	0.90	1	0.29	15	1.08	34	0.89	22	1.08	5	0.54	-0.02	-0.03
LEUKAEMIAS	124	0.88	146	0.99	22	<b>3.61</b>	19	0.78	63	0.95	31	0.89	11	0.71	-0.07	0.00
LYMPHOID LEUKAEMIAS	54	0.81	73	1.05	19	<b>6.52</b>	6	0.52	26	0.82	15	0.92	7	0.98	-0.05	0.01
MYELOID LEUKAEMIAS	61	0.95	64	0.96	3	1.11	10	0.92	32	1.07	15	0.94	4	0.55	-0.01	-0.01
OTHER LEUKAEMIAS	9	0.87	9	0.83	0	0.00	3	1.65	5	1.03	1	0.40	0	0.00	-0.01	-0.01
OTHER AND ILL DEFINED SITES	233	<b>0.71</b>	266	<b>0.78</b>	33	<b>2.40</b>	28	<b>0.51</b>	104	<b>0.68</b>	61	<b>0.75</b>	40	1.05	<b>-0.36</b>	<b>-0.28</b>

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio



**WOMEN** FIRST CANCER SITE  
**COLON**

**COLON**  
**POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**COLON**  
**POOL AIRTUM 1976-2010, DONNE:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
<b>SECOND CANCER SITE</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>EAR</b>	<b>EAR</b>
<b>ALL SITES, BUT SKIN AND COLON</b>	3086	<b>1.04</b>	3578	<b>1.16</b>	492	<b>4.11</b>	472	0.99	1416	<b>1.06</b>	779	1.02	419	1.04	0.42	<b>1.76</b>
HEAD AND NECK	43	1.03	44	1.02	1	0.60	4	0.60	18	0.96	15	1.41	6	1.07	0.01	0.00
ORAL CAVITY	24	1.03	25	1.03	1	1.09	2	0.55	8	0.77	9	1.48	5	1.50	0.00	0.00
PHARYNX	9	1.07	9	1.03	0	0.00	1	0.71	5	1.29	3	1.43	0	0.00	0.00	0.00
LARYNX	10	1.02	10	0.98	0	0.00	1	0.62	5	1.12	3	1.22	1	0.80	0.00	0.00
OESOPHAGUS	13	0.74	14	0.76	1	1.41	2	0.73	6	0.77	3	0.65	2	0.79	-0.02	-0.02
STOMACH	235	1.06	250	1.08	15	1.61	21	<b>0.59</b>	109	1.11	58	1.01	47	<b>1.56</b>	0.05	0.07
COLON RECTUM	163	<b>0.30</b>	208	<b>0.37</b>	45	<b>2.06</b>	31	<b>0.36</b>	91	<b>0.38</b>	18	<b>0.13</b>	23	<b>0.30</b>	<b>-1.46</b>	<b>-1.32</b>
COLON	14	<b>0.04</b>	22	<b>0.05</b>	8	0.51	3	<b>0.05</b>	9	<b>0.05</b>	1	<b>0.01</b>	1	<b>0.02</b>	<b>-1.45</b>	<b>-1.42</b>
RECTUM	149	0.98	186	<b>1.18</b>	37	<b>6.02</b>	28	1.16	82	1.21	17	<b>0.43</b>	22	1.07	-0.01	0.10
LIVER	64	<b>0.67</b>	82	0.82	18	<b>4.68</b>	7	<b>0.46</b>	26	<b>0.61</b>	18	0.72	13	0.96	<b>-0.12</b>	-0.06
GALLBLADDER	48	<b>0.61</b>	59	<b>0.72</b>	11	<b>3.43</b>	6	0.48	23	<b>0.66</b>	9	<b>0.44</b>	10	0.91	<b>-0.12</b>	-0.08
PANCREAS	139	0.94	143	0.93	4	0.70	15	0.67	65	1.01	38	0.97	21	0.95	-0.03	-0.04
LUNG	261	<b>1.21</b>	296	<b>1.33</b>	35	<b>4.22</b>	30	0.90	122	<b>1.29</b>	70	1.25	39	1.27	<b>0.17</b>	<b>0.26</b>
SKIN MELANOMA	59	1.06	70	1.21	11	<b>5.01</b>	9	1.01	23	0.92	18	1.25	9	1.21	0.01	0.04
MESOTHELIOMA	5	0.57	8	0.88	3	<b>9.02</b>	1	0.74	1	0.26	1	0.44	2	1.59	-0.01	0.00
KAPOSI SARCOMA	7	1.40	8	1.54	1	4.99	0	0.00	4	1.84	3	2.31	0	0.00	0.01	0.01
SOFT TISSUE	12	0.89	14	0.99	2	3.72	5	2.33	2	0.33	3	0.86	2	1.07	-0.01	0.00
BONE	3	0.82	4	1.05	1	6.47	0	0.00	1	0.61	2	2.15	0	0.00	0.00	0.00
BREAST	865	<b>1.11</b>	993	<b>1.22</b>	128	<b>4.05</b>	144	1.13	394	<b>1.11</b>	231	<b>1.17</b>	96	0.96	<b>0.32</b>	<b>0.66</b>
CERVIX UTERI	42	1.08	51	1.26	9	<b>5.19</b>	8	1.16	22	1.21	10	1.07	2	0.45	0.01	0.04
CORPUS UTERI	181	<b>1.29</b>	208	<b>1.42</b>	27	<b>4.66</b>	21	0.89	86	<b>1.33</b>	51	<b>1.45</b>	23	1.33	<b>0.15</b>	<b>0.23</b>
OVARY	151	<b>1.51</b>	168	<b>1.61</b>	17	<b>4.15</b>	40	<b>2.44</b>	84	<b>1.85</b>	16	0.63	11	0.85	<b>0.19</b>	<b>0.23</b>
KIDNEY AND RENAL PELVIS	104	<b>1.29</b>	195	<b>2.33</b>	91	<b>29.17</b>	21	<b>1.67</b>	48	1.34	23	1.10	12	1.07	<b>0.09</b>	<b>0.41</b>
BLADDER AND URINARY TRACT	175	<b>1.30</b>	206	<b>1.47</b>	31	<b>5.83</b>	36	<b>1.72</b>	72	1.21	42	1.19	25	1.30	<b>0.15</b>	<b>0.24</b>
URINARY BLADDER	160	<b>1.28</b>	188	<b>1.45</b>	28	<b>5.67</b>	34	<b>1.75</b>	65	1.18	40	1.22	21	1.18	<b>0.13</b>	<b>0.21</b>
URINARY TRACT	15	1.51	18	<b>1.75</b>	3	<b>7.92</b>	2	1.35	7	1.63	2	0.76	4	2.66	0.02	0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	44	0.93	45	0.92	1	0.53	1	<b>0.13</b>	20	0.95	13	1.08	10	1.59	-0.01	-0.01
THYROID	59	1.25	61	1.24	2	1.05	7	0.88	32	<b>1.46</b>	16	1.36	4	0.70	0.04	0.04
HODGKIN LYMPHOMA	7	1.00	8	1.10	1	3.30	0	0.00	3	0.92	2	1.17	2	2.43	0.00	0.00
NON-HODGKIN LYMPHOMA	123	0.99	137	1.06	14	<b>2.85</b>	22	1.12	46	0.83	42	1.31	13	0.77	0.00	0.03
MYELOMA	49	0.81	52	0.83	3	1.24	9	0.94	18	0.67	12	0.77	10	1.20	-0.04	-0.04
LEUKAEMIAS	76	0.87	86	0.95	10	<b>2.83</b>	4	<b>0.29</b>	40	1.03	20	0.88	12	0.99	-0.04	-0.02
LYMPHOID LEUKAEMIAS	29	0.75	37	0.92	8	<b>5.04</b>	2	0.32	14	0.81	8	0.80	5	0.96	-0.04	-0.01
MYELOID LEUKAEMIAS	40	0.98	42	0.99	2	1.24	2	0.31	23	1.28	8	0.75	7	1.21	0.00	0.00
OTHER LEUKAEMIAS	7	0.87	7	0.84	0	0.00	0	0.00	3	0.86	4	1.90	0	0.00	0.00	0.00
OTHER AND ILL DEFINED SITES	172	<b>0.63</b>	190	<b>0.67</b>	18	1.68	31	0.75	69	<b>0.58</b>	46	<b>0.64</b>	26	<b>0.65</b>	<b>-0.38</b>	<b>-0.34</b>

■ Decrease/Difetto    ○ Observed cases    ■ SIR Standardized Incidence Ratio    ■ EAR Excess Absolute Risk  
■ Increase/Eccesso    ○ Casi osservati    ■ Rapporto standardizzato di incidenza    ■ Eccesso assoluto di rischio